Ankündigung • Jun 30
Liaoning Oxiranchem,Inc. to Report First Half, 2026 Results on Aug 25, 2026 Liaoning Oxiranchem,Inc. announced that they will report first half, 2026 results on Aug 25, 2026 New Risk • Apr 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results. Reported Earnings • Apr 28
Full year 2025 earnings released: EPS: CN¥0.01 (vs CN¥0.23 loss in FY 2024) Full year 2025 results: EPS: CN¥0.01 (up from CN¥0.23 loss in FY 2024). Revenue: CN¥4.23b (down 1.4% from FY 2024). Net income: CN¥6.80m (up CN¥166.0m from FY 2024). Profit margin: 0.2% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Ankündigung • Apr 28
Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026 Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China Ankündigung • Mar 31
Liaoning Oxiranchem,Inc. to Report Q1, 2026 Results on Apr 28, 2026 Liaoning Oxiranchem,Inc. announced that they will report Q1, 2026 results on Apr 28, 2026 New Risk • Mar 08
New major risk - Revenue and earnings growth Earnings have declined by 60% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Earnings have declined by 60% per year over the past 5 years. Ankündigung • Dec 31
Liaoning Oxiranchem,Inc. to Report Fiscal Year 2025 Results on Apr 28, 2026 Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2025 results on Apr 28, 2026 New Risk • Nov 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change). Reported Earnings • Oct 27
Third quarter 2025 earnings released: CN¥0.013 loss per share (vs CN¥0.05 loss in 3Q 2024) Third quarter 2025 results: CN¥0.013 loss per share (improved from CN¥0.05 loss in 3Q 2024). Revenue: CN¥1.12b (down 4.9% from 3Q 2024). Net loss: CN¥7.86m (loss narrowed 76% from 3Q 2024). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Ankündigung • Sep 30
Liaoning Oxiranchem,Inc. to Report Q3, 2025 Results on Oct 27, 2025 Liaoning Oxiranchem,Inc. announced that they will report Q3, 2025 results on Oct 27, 2025 Ankündigung • Sep 12
Liaoning Oxiranchem,Inc. Approves Board Appointments Liaoning Oxiranchem,Inc. at its EGM held on September 10, 2025, approved the appointment of Ren Jiangang and Liu Guocheng as independent directors. New Risk • Sep 04
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (7.9% average weekly change). Ankündigung • Jul 02
Liaoning Oxiranchem,Inc. to Report First Half, 2025 Results on Aug 26, 2025 Liaoning Oxiranchem,Inc. announced that they will report first half, 2025 results on Aug 26, 2025 New Risk • Jun 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (11% average weekly change). Reported Earnings • Apr 23
First quarter 2025 earnings released: CN¥0.005 loss per share (vs CN¥0.12 loss in 1Q 2024) First quarter 2025 results: CN¥0.005 loss per share (improved from CN¥0.12 loss in 1Q 2024). Revenue: CN¥943.0m (up 25% from 1Q 2024). Net loss: CN¥3.28m (loss narrowed 96% from 1Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. Ankündigung • Apr 22
Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025 Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning China New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Ankündigung • Mar 31
Liaoning Oxiranchem,Inc. to Report Q1, 2025 Results on Apr 22, 2025 Liaoning Oxiranchem,Inc. announced that they will report Q1, 2025 results on Apr 22, 2025 Ankündigung • Dec 31
Liaoning Oxiranchem,Inc. to Report Fiscal Year 2024 Results on Apr 22, 2025 Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2024 results on Apr 22, 2025 New Risk • Nov 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). Reported Earnings • Oct 28
Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.061 loss in 3Q 2023) Third quarter 2024 results: CN¥0.05 loss per share (improved from CN¥0.061 loss in 3Q 2023). Revenue: CN¥1.17b (up 24% from 3Q 2023). Net loss: CN¥32.7m (loss narrowed 25% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Ankündigung • Sep 30
Liaoning Oxiranchem,Inc. to Report Q3, 2024 Results on Oct 28, 2024 Liaoning Oxiranchem,Inc. announced that they will report Q3, 2024 results on Oct 28, 2024 New Risk • Sep 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Reported Earnings • Aug 06
Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.13 loss in 2Q 2023) Second quarter 2024 results: CN¥0.032 loss per share (improved from CN¥0.13 loss in 2Q 2023). Revenue: CN¥1.08b (down 2.1% from 2Q 2023). Net loss: CN¥22.4m (loss narrowed 75% from 2Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Ankündigung • Jun 29
Liaoning Oxiranchem,Inc. to Report First Half, 2024 Results on Aug 06, 2024 Liaoning Oxiranchem,Inc. announced that they will report first half, 2024 results on Aug 06, 2024 Reported Earnings • Apr 24
First quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.09 loss in 1Q 2023) First quarter 2024 results: CN¥0.12 loss per share (further deteriorated from CN¥0.09 loss in 1Q 2023). Revenue: CN¥757.1m (down 19% from 1Q 2023). Net loss: CN¥78.4m (loss widened 30% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Ankündigung • Apr 23
Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024 Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning China New Risk • Apr 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Ankündigung • Mar 30
Liaoning Oxiranchem,Inc. to Report Q1, 2024 Results on Apr 23, 2024 Liaoning Oxiranchem,Inc. announced that they will report Q1, 2024 results on Apr 23, 2024 Ankündigung • Dec 30
Liaoning Oxiranchem,Inc. to Report Fiscal Year 2023 Results on Apr 23, 2024 Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2023 results on Apr 23, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: CN¥0.061 loss per share (vs CN¥0.067 loss in 3Q 2022) Third quarter 2023 results: CN¥0.061 loss per share. Revenue: CN¥949.3m (down 35% from 3Q 2022). Net loss: CN¥43.6m (loss widened 12% from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Reported Earnings • Aug 29
Second quarter 2023 earnings released: CN¥0.13 loss per share (vs CN¥0.074 loss in 2Q 2022) Second quarter 2023 results: CN¥0.13 loss per share (further deteriorated from CN¥0.074 loss in 2Q 2022). Revenue: CN¥1.10b (down 30% from 2Q 2022). Net loss: CN¥89.8m (loss widened 73% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 19
Full year 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.52 in FY 2021) Full year 2022 results: EPS: CN¥0.01 (down from CN¥0.52 in FY 2021). Revenue: CN¥5.64b (down 16% from FY 2021). Net income: CN¥5.60m (down 98% from FY 2021). Profit margin: 0.1% (down from 5.2% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥10.05, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 28x in the Chemicals industry in China. Total returns to shareholders of 82% over the past three years. Price Target Changed • Nov 16
Price target decreased to CN¥11.00 Down from CN¥13.87, the current price target is provided by 1 analyst. New target price is 25% above last closing price of CN¥8.77. Stock is down 48% over the past year. The company is forecast to post earnings per share of CN¥0.64 for next year compared to CN¥0.52 last year. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 28
Third quarter 2022 earnings released: CN¥0.031 loss per share (vs CN¥0.16 profit in 3Q 2021) Third quarter 2022 results: CN¥0.031 loss per share (down from CN¥0.16 profit in 3Q 2021). Revenue: CN¥1.46b (down 22% from 3Q 2021). Net loss: CN¥39.0m (down 136% from profit in 3Q 2021). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Board Change • Oct 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 08
Liaoning Oxiranchem,Inc. Approves Election Directors Liaoning Oxiranchem,Inc. approved Election of non-independent directors to be: Zhu Jianmin; Dong Zhenpeng; Liu Zhaobin; Song Enjun; Huang Guanxiong & Fan Xiaoping and Election of independent directors to be Xiong Yanren; Yang Xianghong & Bu Xinping. Valuation Update With 7 Day Price Move • Sep 06
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥11.15, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 109% over the past three years. Reported Earnings • Aug 24
Second quarter 2022 earnings released: CN¥0.074 loss per share (vs CN¥0.043 profit in 2Q 2021) Second quarter 2022 results: CN¥0.074 loss per share (down from CN¥0.043 profit in 2Q 2021). Revenue: CN¥1.58b (down 9.0% from 2Q 2021). Net loss: CN¥52.0m (down 261% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 22%, compared to a 42% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • May 24
Liaoning Oxiranchem,Inc. Approves Final Cash Dividend for the Year 2021 Liaoning Oxiranchem,Inc. approved final cash dividend (tax included) of CNY 3.4200000 per 10 shares for the year 2021, at its AGM, held on May 20, 2022. Ankündigung • May 02
Liaoning Oxiranchem,Inc. Proposes Final Cash Dividend for the Year 2021 Liaoning Oxiranchem,Inc. proposed final cash dividend (tax included) of CNY 3.4200000 per 10 shares for the year 2021. Reported Earnings • Apr 30
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.08 in 1Q 2021). Revenue: CN¥1.34b (down 3.1% from 1Q 2021). Net income: CN¥99.7m (up 95% from 1Q 2021). Profit margin: 7.4% (up from 3.7% in 1Q 2021). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 33%. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 18
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥0.53 (down from CN¥0.59 in FY 2020). Revenue: CN¥6.72b (up 18% from FY 2020). Net income: CN¥357.2m (down 11% from FY 2020). Profit margin: 5.3% (down from 7.1% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 100%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 26%, compared to a 48% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 8% per year. Reported Earnings • Oct 23
Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.24 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥1.87b (up 22% from 3Q 2020). Net income: CN¥109.9m (down 32% from 3Q 2020). Profit margin: 5.9% (down from 11% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥19.15, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 357% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥9.25 per share. Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥22.79, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Chemicals industry in China. Total returns to shareholders of 372% over the past three years. Valuation Update With 7 Day Price Move • Sep 03
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥15.41, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 21x in the Chemicals industry in China. Total returns to shareholders of 217% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥8.51 per share. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS CN¥0.043 (vs CN¥0.18 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥1.73b (up 10% from 2Q 2020). Net income: CN¥32.3m (down 74% from 2Q 2020). Profit margin: 1.9% (down from 8.0% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Aug 24
Price target decreased to CN¥12.50 Down from CN¥13.87, the current price target is an average from 3 analysts. New target price is 35% below last closing price of CN¥19.17. Stock is up 119% over the past year. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 29% share price gain to CN¥16.49, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 269% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥7.79 per share. Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥12.40, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 205% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥7.74 per share. Ankündigung • May 22
Liaoning Oxiranchem,Inc. Approves Final Cash Dividend Liaoning Oxiranchem,Inc. announced at the AGM held on 20, 2021 that the company approved Cash dividend/10 shares (tax included) of CNY 3.57000000 for year 2020. Price Target Changed • Apr 21
Price target increased to CN¥14.13 Up from CN¥13.08, the current price target is an average from 4 analysts. New target price is 45% above last closing price of CN¥9.78. Stock is up 60% over the past year. Reported Earnings • Apr 12
Full year 2020 earnings released: EPS CN¥0.59 (vs CN¥0.51 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥5.71b (down 9.2% from FY 2019). Net income: CN¥403.0m (up 16% from FY 2019). Profit margin: 7.1% (up from 5.5% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 17% per year and the company’s share price has also increased by 17% per year. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥9.78, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 74% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥5.64 per share. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥11.28, the stock is trading at a trailing P/E ratio of 19.1x, down from the previous P/E ratio of 23.1x. This compares to an average P/E of 36x in the Chemicals industry in China. Total returns to shareholders over the past three years are 89%. Ankündigung • Mar 09
Liaoning Oxiranchem,Inc. to Report Fiscal Year 2020 Results on Apr 20, 2021 Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2020 results on Apr 20, 2021 Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥12.54, the stock is trading at a trailing P/E ratio of 21.3x, down from the previous P/E ratio of 25.9x. This compares to an average P/E of 35x in the Chemicals industry in China. Total returns to shareholders over the past three years are 130%. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥12.80, the stock is trading at a trailing P/E ratio of 21.7x, down from the previous P/E ratio of 26.3x. This compares to an average P/E of 34x in the Chemicals industry in China. Total returns to shareholders over the past three years are 115%. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 30% share price gain to CN¥12.50, the stock is trading at a trailing P/E ratio of 21.2x, up from the previous P/E ratio of 16.3x. This compares to an average P/E of 35x in the Chemicals industry in China. Total returns to shareholders over the past three years are 105%. Is New 90 Day High Low • Jan 04
New 90-day high: CN¥12.50 The company is up 44% from its price of CN¥8.68 on 30 September 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥5.17 per share. Is New 90 Day High Low • Dec 12
New 90-day low: CN¥8.37 The company is down 2.0% from its price of CN¥8.55 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥7.12 per share. Ankündigung • Nov 19
Liaoning Oxiranchem,Inc. (SZSE:300082) signed the agreement to acquire 67% stake in Liaoning Oxiranphex Inc. from Oxiranchem Holding Group Co., Ltd. and Dalian Jixing Venture Capital Partnership Enterprise (Limited Partnership) for approximately CNY 170 million. Liaoning Oxiranchem,Inc. (SZSE:300082) signed the agreement to acquire 67% stake in Liaoning Oxiranphex Inc. from Oxiranchem Holding Group Co., Ltd. and Dalian Jixing Venture Capital Partnership Enterprise (Limited Partnership) for approximately CNY 170 million on November 17, 2020. Liaoning Oxiranchem,Inc. shall pay 51% of consideration within five working days after the approval from the shareholders and remaining 49% within 60 days from the completion. As of June 30, 2020, Liaoning Oxiranphex Inc. has reported total assets of CNY 206.55 million and net assets of CNY 108.22 million. The transaction is subject to approval from the shareholders of Liaoning Oxiranchem,Inc. while its Board of Directors has approved the transaction. Is New 90 Day High Low • Nov 16
New 90-day high: CN¥11.15 The company is up 21% from its price of CN¥9.25 on 18 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥6.37 per share. Is New 90 Day High Low • Oct 28
New 90-day high: CN¥11.00 The company is up 30% from its price of CN¥8.44 on 30 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.34 per share. Reported Earnings • Oct 23
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥402.1m, up 27% from the prior year. Total revenue was CN¥5.54b over the last 12 months, down 14% from the prior year. Valuation Update With 7 Day Price Move • Oct 13
Market bids up stock over the past week After last week's 15% share price gain to CN¥10.01, the stock is trading at a trailing P/E ratio of 19.7x, up from the previous P/E ratio of 17.1x. This compares to an average P/E of 40x in the Chemicals industry in China. Total returns to shareholders over the past three years are 51%. Is New 90 Day High Low • Oct 13
New 90-day high: CN¥10.01 The company is up 40% from its price of CN¥7.14 on 15 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥6.62 per share. Ankündigung • Sep 10
Liaoning Oxiranchem,Inc. (SZSE:300082) signed an agreement to acquire 24.24% stake in Suzhou Huayi new energy technology co., LTD. from Gu Hongxia for CNY 40 million. Liaoning Oxiranchem,Inc. (SZSE:300082) signed an agreement to acquire 24.24% stake in Suzhou Huayi new energy technology co., LTD. from Gu Hongxia for CNY 40 million on September 8, 2020. Liaoning Oxiranchem will also increase the capital of Suzhou Huayi new energy technology with CNY 27.307 million in cash, after the investment is completed, Liaoning Oxiranchem will hold a total of 35% in Suzhou Huayi new energy technology. Suzhou Huayi new energy technology generated the revenues of CNY 93.1 million, operating profit of CNY 9.1 million and net profit of CNY 6.9 million for the year ended December 31, 2019.. As of December 31, 2019, Suzhou Huayi new energy technology has total assets of CNY 158.1 million and owner equity of CNY 75.3 million. The transaction has been approved by the Board of Directors of Liaoning Oxiranchem and does not need to be submitted to the Liaoning Oxiranchem's shareholders meeting for deliberation. Ankündigung • Jul 24
Liaoning Oxiranchem,Inc. to Report First Half, 2020 Results on Aug 20, 2020 Liaoning Oxiranchem,Inc. announced that they will report first half, 2020 results on Aug 20, 2020 
